Skip to content
Aminoscope
Goal

Injury recovery & tissue repair

“Healing” peptides are among the most-hyped in the space. The biology is genuinely interesting, but for most of these the controlled human evidence is thin and the compounds are unapproved and gray-market. Here is what each is actually supported to do.

The repair peptides

BPC-157, TB-500, and their newer stand-ins — the core of the recovery category.

PENTADECAPEPTIDE BPC 157 · TISSUE-REPAIR HYPOTHESISproposed repair — mostly rodent data

BPC 157: what the evidence actually shows (and what it doesn't)

The 'healing peptide' has a deep rodent literature and almost no human data. A straight read of where the science stands.

THYMOSIN β4 (TB-500) · ACTIN-SEQUESTERING PEPTIDEbound G-actin

TB-500 and thymosin beta-4: separating the trials from the hype

Real Phase 2 dry-eye data, deep preclinical neuro/cardiac work, and a recovery-market use that was never actually tested.

BPC-157TB-500THE “WOLVERINE STACK” · COMBINED RECOVERY PROTOCOLclaimed synergy — untestedtwo preclinical peptides, zero combination trials

The BPC-157 + TB-500 blend (“Wolverine stack”): popular, but proven?

The combined recovery protocol has a tidy mechanistic story and zero combination trials. A straight read of what the blend is, the theory, and the gaps.

BPC-157 vs TB-500: two recovery peptides on the same evidence ladderrecovery RCTother-use humananimal in vivocell / mechanismBPC-157TB-500 / thymosin β4Same rungs, neither reaches the topBOTH PRECLINICAL FOR RECOVERY · NO HUMAN RCT

BPC-157 vs TB-500: the recovery peptide pair, graded on evidence

They're sold as a matched 'healing stack,' but BPC-157 and TB-500 are unrelated molecules with different mechanisms — and the same honest ceiling: overwhelmingly preclinical for recovery, with no human randomized trials.

assumption, not a findingPDA · no direct dataPENTADECA ARGINATE · A BORROWED EVIDENCE BASEBPC 157 — rodent studiesA REPOSITIONING AS MUCH AS A MOLECULE

Pentadeca Arginate (PDA): the evidence behind the BPC 157 successor

PDA is marketed as a more stable upgrade on BPC 157 — but it has almost no research of its own. A straight read of a borrowed evidence base.

Joints, tendons & skin

Targeted recovery — connective tissue, cartilage, and skin repair.

Gut & immune repair

The gut-lining and immune-modulating peptides used in recovery protocols.

LARAZOTIDE · AT-1001 · TIGHT-JUNCTION REGULATORgut lumen · gluten peptidesepithelial cellepithelial cellAT-1001tight junctiontightens the gut seal — celiac Phase 3 missed

Larazotide: the leaky-gut peptide that failed its Phase 3 trial

An 8-amino-acid tight-junction regulator with real celiac data and a failed pivotal trial — and why the supplement use runs far ahead of the evidence.

KPV, a melanocortin tripeptide, calming intestinal inflammation — preclinical evidence onlyKPVPRECLINICALKPV tripeptideinflamed gut (mouse models)KPV · THE C-TERMINAL TRIPEPTIDE OF α-MSH · WHAT THE EVIDENCE SHOWS

KPV peptide: what the evidence actually shows (benefits, dosage talk, and side effects)

KPV is the anti-inflammatory tripeptide tail of α-MSH, sold for gut, inflammation, wound-healing and skin. The mechanism is real and the mouse data are real — but there are essentially no human trials. A straight read of where the science stands.

Thymosin alpha-1: a thymic immune peptide, approved abroad for specific usesAPPROVEDABROADthymusimmune cellsTHYMOSIN α1 (Tα1) · A THYMIC IMMUNE PEPTIDEreal drug abroad — for specific immune uses, not general “wellness”

Thymosin alpha-1 (Tα1): a real immune drug abroad, read against the wellness pitch

Tα1 (brand Zadaxin) is an approved immunomodulator in dozens of countries — for hepatitis, sepsis and severe infection, supervised. It is not FDA-approved, not the same as TB-500, and not the general anti-aging injectable sold online. The honest evidence, dosing and side-effect read.

EPOclassic EPO receptorred cells — no erythropoiesisinnate repair receptor (EPOR/CD131)tissue protection, healingARA-290 (cibinetide): an 11-aa peptide from EPOARA-290 · CIBINETIDE · INVESTIGATIONAL · PHASE 2

ARA-290 (cibinetide): the EPO-derived repair peptide and what its trials actually show

An 11-amino-acid peptide engineered from erythropoietin to protect tissue without making red cells. A straight read of the small-fiber-neuropathy evidence — and its limits.

Explore by goal